Scandinavian ChemoTech (CMOTEC) Q2 2025 earnings summary

Executive summary

• Achieved world's first completed scientific trial validating TSE technology in veterinary oncology, supporting long-term growth and profitability.

• Record-breaking Q2 sales in Animal Care, with USD 390,000 in the US, representing 60% of total 2024 revenue in a single quarter.

• H1 2025 revenue nearly matches last year's full-year figures, driven by strong US market adoption.

• Operational restructuring in late 2024 led to annual savings of 2-3 MSEK, reinvested in commercial activities.

• Directed share issue post-Q2 raised SEK 4.85 million, strengthening capital and strategic value.

Financial highlights

• Q2 2025 net sales: 3,841 KSEK (1,681 KSEK Q2 2024); H1 2025 net sales: 6,313 KSEK (3,026 KSEK H1 2024).

• Q2 2025 net loss: -943 KSEK (-4,104 KSEK Q2 2024); H1 2025 net loss: -4,265 KSEK (-7,307 KSEK H1 2024).

• Q2 2025 EPS: -0.04 SEK (-0.23 SEK Q2 2024); H1 2025 EPS: -0.18 SEK (-0.41 SEK H1 2024).

• Cash flow from operating activities Q2 2025: -504 KSEK (-553 KSEK Q2 2024); H1 2025: -1,743 KSEK (-5,406 KSEK H1 2024).

• Equity/assets ratio at June 30: 18% (22% June 2024); cash and cash equivalents: 517 KSEK (1,859 KSEK June 2024).

Outlook and guidance

• Focus on achieving cash flow positivity and strengthening recurring revenues through treatment kits.

• Plans to expand sales in North America and Europe and advance regulatory/scientific validation in India.

• Additional funding required to maintain operations for the next twelve months; management actively addressing financing.